Skip to content

Released May 8, 2025, after the close

10-Q filed May 8, 2025, 38 days after period end · 0001628280-25-023927

Q1 2025 · 10-Q
Revenue$41.46M−7.6% vs Q1 2024−27.9% vs Q4 2024
Net Income-$11.40MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.09N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit$20,157,000−12.4%
Operating Income-$14,975,000N/M
Operating Cash Flow-$125,000N/M
Free Cash Flowderived-$974,000N/M
Margins · derived
Gross margin48.6%−2.7 pt vs Q1 2024
Operating margin-36.1%−12.2 pt vs Q1 2024
Net margin-27.5%−13.8 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$41.46M$44.86M$37.09M$35.06M
Net Income-$11.40M-$6.17M-$6.81M-$2.16M
EPS Diluted-$0.09-$0.05-$0.05$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR